Venus Remedies Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
297.15 +2.65 (0.90%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
290
Today’s High
301.6
52 Week Low
280
52 Week High
429.6
299.85 +6.15 (2.09%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
289.1
Today’s High
301
52 Week Low
281.1
52 Week High
430
Key Metrics
- Market Cap (In Cr) 392.59
- Beta 1.87
- Div. Yield (%) 0
- P/B 0.81
- TTM P/E 20.36
- Peg Ratio -0.72
- Sector P/E 31.15
- D/E 0.08
- Open Price 291
- Prev Close 294.5
Venus Remedies Analysis
Price Analysis
-
1 Week-5.38%
-
3 Months-13.4%
-
6 Month-2.12%
-
YTD-27.7%
-
1 Year-11.7%
Risk Meter
- 48% Low risk
- 48% Moderate risk
- 48% Balanced Risk
- 48% High risk
- 48% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 0
- 0
- 0
- 0
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 1
- 1
- 1
- 1
Venus Remedies News
Smallcap pharma stock hits over 8% upper circuit; What drove the rally?
1 min read . 21 Dec 2023Venus Remedies locked at 5% upper circuit on nod to market Meropenem in Spain
1 min read . 22 Jun 2023Venus Remedies Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 601.45
- Selling/ General/ Admin Expenses Total
- 171.32
- Depreciation/ Amortization
- 26.44
- Total Operating Expense
- 568.29
- Operating Income
- 33.16
- Net Income Before Taxes
- 44.65
- Net Income
- 28.5
- Diluted Normalized EPS
- 21.13
- Period
- 2024
- Total Assets
- 626.83
- Total Liabilities
- 139.28
- Total Equity
- 487.55
- Tangible Book Valueper Share Common Eq
- 300.93
- Period
- 2024
- Cashfrom Operating Activities
- 37.28
- Cashfrom Investing Activities
- -7.21
- Cashfrom Financing Activities
- -1.08
- Net Changein Cash
- 27.74
- Period
- 2023
- Total Revenue
- 555.51
- Selling/ General/ Admin Expenses Total
- 129.25
- Depreciation/ Amortization
- 32.3
- Other Operating Expenses Total
- -0.49
- Total Operating Expense
- 527.12
- Operating Income
- 28.39
- Net Income Before Taxes
- 37.93
- Net Income
- 26.57
- Diluted Normalized EPS
- 19.87
- Period
- 2023
- Total Assets
- 601.08
- Total Liabilities
- 140.74
- Total Equity
- 460.34
- Tangible Book Valueper Share Common Eq
- 285.1
- Period
- 2023
- Cashfrom Operating Activities
- 36.63
- Cashfrom Investing Activities
- -50.83
- Cashfrom Financing Activities
- -0.57
- Net Changein Cash
- -22.04
- Period
- 2022
- Total Revenue
- 598.65
- Selling/ General/ Admin Expenses Total
- 128.05
- Depreciation/ Amortization
- 33.53
- Other Operating Expenses Total
- -0.46
- Total Operating Expense
- 569.61
- Operating Income
- 29.04
- Net Income Before Taxes
- 36.41
- Net Income
- 40.72
- Diluted Normalized EPS
- 30.86
- Period
- 2022
- Total Assets
- 579.82
- Total Liabilities
- 139.37
- Total Equity
- 440.45
- Tangible Book Valueper Share Common Eq
- 263.72
- Period
- 2022
- Cashfrom Operating Activities
- 41
- Cashfrom Investing Activities
- -16.63
- Cashfrom Financing Activities
- -9.48
- Net Changein Cash
- 14.38
- Period
- 2021
- Total Revenue
- 548.12
- Selling/ General/ Admin Expenses Total
- 137.8
- Depreciation/ Amortization
- 35.28
- Total Operating Expense
- 506.18
- Operating Income
- 41.94
- Net Income Before Taxes
- 48.55
- Net Income
- 61.77
- Diluted Normalized EPS
- 37.7
- Period
- 2021
- Total Assets
- 555.85
- Total Liabilities
- 155.57
- Total Equity
- 400.28
- Tangible Book Valueper Share Common Eq
- 245.96
- Period
- 2021
- Cashfrom Operating Activities
- 131.84
- Cashfrom Investing Activities
- 56.49
- Cashfrom Financing Activities
- -162.24
- Net Changein Cash
- 26.94
- Period
- 2020
- Total Revenue
- 339.33
- Selling/ General/ Admin Expenses Total
- 109.95
- Depreciation/ Amortization
- 32.01
- Total Operating Expense
- 339.34
- Operating Income
- -0.01
- Net Income Before Taxes
- -8.04
- Net Income
- -10
- Diluted Normalized EPS
- -3.46
- Period
- 2020
- Total Assets
- 643.77
- Total Liabilities
- 320.4
- Total Equity
- 323.37
- Tangible Book Valueper Share Common Eq
- 176.58
- Period
- 2020
- Cashfrom Operating Activities
- 77.6
- Cashfrom Investing Activities
- -4.75
- Cashfrom Financing Activities
- -73
- Net Changein Cash
- -0.09
- Period
- 2019
- Total Revenue
- 321.89
- Selling/ General/ Admin Expenses Total
- 92.76
- Depreciation/ Amortization
- 33.98
- Total Operating Expense
- 332.31
- Operating Income
- -10.42
- Net Income Before Taxes
- -29.73
- Net Income
- -28.58
- Diluted Normalized EPS
- -18.43
- Period
- 2019
- Total Assets
- 732.83
- Total Liabilities
- 400.3
- Total Equity
- 332.52
- Tangible Book Valueper Share Common Eq
- 133.3
- Period
- 2019
- Cashfrom Operating Activities
- 45.33
- Cashfrom Investing Activities
- -11.33
- Cashfrom Financing Activities
- -35.17
- Net Changein Cash
- -1.17
- Period
- 2018
- Total Revenue
- 372.41
- Selling/ General/ Admin Expenses Total
- 39.31
- Depreciation/ Amortization
- 33.83
- Other Operating Expenses Total
- 66.62
- Total Operating Expense
- 366.77
- Operating Income
- 5.64
- Net Income Before Taxes
- -27.53
- Net Income
- -30.69
- Diluted Normalized EPS
- -24.87
- Period
- 2018
- Total Assets
- 750.85
- Total Liabilities
- 388.94
- Total Equity
- 361.91
- Tangible Book Valueper Share Common Eq
- 146.88
- Period
- 2018
- Cashfrom Operating Activities
- 31.19
- Cashfrom Investing Activities
- -11.48
- Cashfrom Financing Activities
- -39.23
- Net Changein Cash
- -19.52
- Period
- 2024-09-30
- Total Revenue
- 167.45
- Selling/ General/ Admin Expenses Total
- 50.05
- Depreciation/ Amortization
- 6.4
- Other Operating Expenses Total
- -0.01
- Total Operating Expense
- 168.94
- Operating Income
- -1.49
- Net Income Before Taxes
- 9.07
- Net Income
- 3.51
- Diluted Normalized EPS
- 2.63
- Period
- 2024-09-30
- Total Assets
- 660.46
- Total Liabilities
- 166.25
- Total Equity
- 494.21
- Tangible Book Valueper Share Common Eq
- 287.24
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 25.59
- Cashfrom Investing Activities
- -41.8
- Cashfrom Financing Activities
- -0.45
- Net Changein Cash
- -17.64
- Period
- 2024-06-30
- Total Revenue
- 108.61
- Selling/ General/ Admin Expenses Total
- 35.14
- Depreciation/ Amortization
- 5.98
- Total Operating Expense
- 103.33
- Operating Income
- 5.28
- Net Income Before Taxes
- 6.86
- Net Income
- 1.23
- Diluted Normalized EPS
- 0.92
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 195.16
- Selling/ General/ Admin Expenses Total
- 50.87
- Depreciation/ Amortization
- 5.91
- Total Operating Expense
- 181.6
- Operating Income
- 13.56
- Net Income Before Taxes
- 17.46
- Net Income
- 10.5
- Diluted Normalized EPS
- 7.86
- Period
- 2024-03-31
- Total Assets
- 626.83
- Total Liabilities
- 139.28
- Total Equity
- 487.55
- Tangible Book Valueper Share Common Eq
- 300.93
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 37.28
- Cashfrom Investing Activities
- -7.21
- Cashfrom Financing Activities
- -1.08
- Net Changein Cash
- 27.74
- Period
- 2023-12-31
- Total Revenue
- 143.42
- Selling/ General/ Admin Expenses Total
- 39.47
- Depreciation/ Amortization
- 6.54
- Total Operating Expense
- 137.92
- Operating Income
- 5.5
- Net Income Before Taxes
- 7.78
- Net Income
- 6.85
- Diluted Normalized EPS
- 5.13
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 167.72
- Selling/ General/ Admin Expenses Total
- 47.99
- Depreciation/ Amortization
- 6.44
- Total Operating Expense
- 156.37
- Operating Income
- 11.35
- Net Income Before Taxes
- 14.34
- Net Income
- 9.94
- Diluted Normalized EPS
- 7.44
- Period
- 2023-09-30
- Total Assets
- 640.43
- Total Liabilities
- 169.45
- Total Equity
- 470.98
- Tangible Book Valueper Share Common Eq
- 296.36
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -2.47
- Cashfrom Investing Activities
- 16.98
- Cashfrom Financing Activities
- -0.6
- Net Changein Cash
- 13.96
- Period
- 2023-06-30
- Total Revenue
- 95.15
- Selling/ General/ Admin Expenses Total
- 32.88
- Depreciation/ Amortization
- 7.55
- Total Operating Expense
- 92.3
- Operating Income
- 2.85
- Net Income Before Taxes
- 5.05
- Net Income
- 1.18
- Diluted Normalized EPS
- 0.88
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 155.64
- Selling/ General/ Admin Expenses Total
- 39.29
- Depreciation/ Amortization
- 8.29
- Total Operating Expense
- 139.32
- Operating Income
- 16.32
- Net Income Before Taxes
- 19.73
- Net Income
- 11.06
- Diluted Normalized EPS
- 8.28
- Period
- 2023-03-31
- Total Assets
- 601.08
- Total Liabilities
- 140.74
- Total Equity
- 460.34
- Tangible Book Valueper Share Common Eq
- 285.1
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 36.63
- Cashfrom Investing Activities
- -50.83
- Cashfrom Financing Activities
- -0.57
- Net Changein Cash
- -22.04
- Period
- 2022-12-31
- Total Revenue
- 116.9
- Selling/ General/ Admin Expenses Total
- 32.54
- Depreciation/ Amortization
- 7.22
- Total Operating Expense
- 116.02
- Operating Income
- 0.88
- Net Income Before Taxes
- 4.54
- Net Income
- 3.29
- Diluted Normalized EPS
- 2.46
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Venus Remedies Technical
Moving Average
SMA
- 5 Day297.01
- 10 Day306.96
- 20 Day315.08
- 50 Day332.35
- 100 Day353.47
- 300 Day346.56
Venus Remedies Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Zenotech Laboratories
- 76.2
- 0.1
- 0.13
- 107.79
- 52.23
- 465.05
- Gennex Laboratories
- 18.96
- -0.26
- -1.35
- 29
- 13.25
- 431.24
- Venus Remedies
- 297.15
- 2.65
- 0.9
- 429.6
- 280
- 397.29
- Medico Remedies
- 44.8
- -0.79
- -1.73
- 92.87
- 35
- 371.77
- Sanjivani Paranteral
- 284.2
- -5.75
- -1.98
- 360.6
- 122.15
- 332.07
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Zenotech Laboratories
- 55.75
- 5.13
- 16.35
- 31.26
- Gennex Laboratories
- 27.25
- 2.57
- 9.25
- 8.49
- Venus Remedies
- 13.78
- 0.81
- 7.25
- 5.58
- Medico Remedies
- 45.66
- 7.23
- 13.41
- 3.99
- Sanjivani Paranteral
- 54.95
- 12.14
- -
- 9.41
Venus Remedies Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-Oct-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results & A.G.M.
- 20-Jul-24
- Others
- 30-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 14-Jul-23
- Others
- 29-May-23
- Audited Results
- 30-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 23-Sept-24
- 06-Aug-24
- AGM
- 24-Aug-23
- 14-Jul-23
- AGM